ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation

BioKey, ABVC’s wholly owned subsidiary has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products: RGC-1501 for the treatment of non-small cell lung cancer, RGC-1502 for the treatment of pancreatic cancer. and RGC 1503 for the treatment of colorectal cancer patients.
[ABVC Biopharma, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News